Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Zilretta Clear all
Recruiting Phase 3 Interventional

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
30
States / cities
Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

NCT00242580
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 16, 2026, 9:23 PM EDT
Recruiting Phase 1 Interventional

The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis

NCT04929951
View directory record Official record
Conditions
Osteoarthritis Shoulder, Shoulder Pain
Interventions
Micro Fragmented Adipose Tissue, Corticosteroid injection
Biological
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 16, 2026, 9:23 PM EDT
Terminated No phase listed Observational

Comparison of Chitodex Gel Vs NexFoam on Post-operative Outcomes in the Treatment of Chronic Rhinosinusitis

NCT05083741
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Chitogel, Nexfoam
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 16, 2026, 9:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

NCT04008784
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment
Drug
Lead sponsor
Clinical Research Center of the Carolinas
Other
Eligibility
2 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

NCT02255032
View directory record Official record
Conditions
Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
Interventions
4 mg CLS-TA, 0.8 mg CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 16, 2026, 9:23 PM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

NCT03613532
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
Interventions
Venetoclax, Fludarabine, Busulfan, Azacitidine, Decitabine/cedazuridine
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 16, 2026, 9:23 PM EDT
Withdrawn Not applicable Interventional

Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis

NCT02420925
View directory record Official record
Conditions
Gastroparesis
Interventions
Celiac Plexus Block
Procedure
Lead sponsor
Linda Nguyen
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Kybella With Triamcinolone

NCT03361176
View directory record Official record
Conditions
Adiposity
Interventions
Injectable sodium deoxycholate, Injectable sodium deoxycholate with Triamcinolone acetate
Drug · Combination Product
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Diego, California • Hunt Valley, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02303184
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
4 mg CLS-TA, Sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata

NCT01797432
View directory record Official record
Conditions
Alopecia Areata
Interventions
Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10), Restylane
Drug · Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 16, 2026, 9:23 PM EDT
Completed No phase listed Observational

Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis

NCT00189449
View directory record Official record
Conditions
Allergic Rhinitis, Allergy, Growth
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 13 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2008 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy

NCT00411333
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
triamcinolone acetonide (Kenalog)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

NCT05436535
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 16, 2026, 9:23 PM EDT
Withdrawn Not applicable Interventional

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

NCT02457026
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Aflibercept, Triamcinolone Acetonide, Verteporfin
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 16, 2026, 9:23 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo

NCT02191748
View directory record Official record
Conditions
Vitiligo
Interventions
Needling, Triamcinolone
Procedure · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Phase 3 Interventional Results available

TAC Versus TC for Adjuvant Breast Cancer

NCT00493870
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 16, 2026, 9:23 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Granulation Tissue Treatment: Silver Nitrate vs Kenalog vs Washcloth Abrasion

NCT02519738
View directory record Official record
Conditions
Other Abnormal Granulation Tissue Nos
Interventions
Silver Nitrate, Kenalog (Triamcinolone), Washcloth Abrasion
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
Up to 17 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Not applicable Interventional Results available

Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection

NCT02084706
View directory record Official record
Conditions
Trigger Finger
Interventions
Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley, 2% Lidocaine, Triamcinolone (20 g), J-tip lidocaine administration, Triamcinolone (20 g) Injection over the A1 pulley.
Procedure · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Sep 16, 2026, 9:23 PM EDT
Terminated Phase 4 Interventional Results available

Intralesional Steroids in the Treatment of Alopecia Areata

NCT01898806
View directory record Official record
Conditions
Alopecia Areata
Interventions
Intralesional Triamcinolone 2.5 mg/ml, Intralesional Triamcinolone 5 mg/ml, Intralesional Triamcinolone 10 mg/ml, Intralesional Saline
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Phase 4 Interventional Results available

Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial)

NCT01238536
View directory record Official record
Conditions
Spinal Stenosis, Low Back Pain
Interventions
Epidural steroid with local anesthetic injection, Epidural local anesthetic injection, Epidural steroid injection, Epidural local anesthetic injection
Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Redwood City, California • Roseville, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 16, 2026, 9:23 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

NCT01547741
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
914
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 16, 2026, 9:23 PM EDT
Withdrawn Phase 4 Interventional

Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

NCT04075136
View directory record Official record
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 16, 2026, 9:23 PM EDT